Eli Lilly and Novo Nordisk both beat Q2 estimates and raised their full-year outlooks, but investors favored Lilly, boosting its shares while punishing Novo. Lilly leads the obesity drug market with a 60.9% U.S. share, driven by strong sales of Mounjaro and Zepbound, and raised its revenue guidance amid sustained demand despite pricing pressures. Novo, holding 38.8% market share, also beat expectations but faced investor concerns over its pipeline and growth prospects, especially after mixed trial results and a weaker-than-expected launch of its Wegovy pill. The diverging investor confidence highlights Lilly as the market momentum leader, while Novo works to regain market share and prove its long-term growth strategy.
The iShares U.S. Pharmaceuticals ETF (IHE) provides focused exposure to the US pharmaceutical sector, heavily weighted towards Johnson & Johnson and Eli Lilly. It benefits from growth drivers like obesity therapies and strong drug pipelines but carri...
Eli Lilly has finalized its acquisition of AtaiBeckley, a clinical-stage biopharmaceutical company focused on developing rapid-acting neuroplastogens for mental health, including treatment-resistant depression. This acquisition aims to introduce inno...
Eli Lilly and NVIDIA both reported strong quarterly results, with Lilly growing 47.7% driven by obesity drugs Mounjaro and Zepbound, and NVIDIA soaring 105.8% on AI data center demand. Lilly focuses on expanding its pharmaceutical portfolio and manuf...
The iShares US Pharmaceuticals ETF (IHE) is rated a hold due to fair valuation and increasing short-term challenges. Its portfolio is heavily concentrated, with 43% in Johnson & Johnson and Eli Lilly, and the top 10 holdings making up 76%. Technical ...
Novartis' failed cholesterol drug trial for pelacarsen caused a sharp 14% drop in its stock and dragged down the entire Lp(a) drug class, hitting Amgen hardest with a 10% decline despite Amgen's positive Phase 3 lung cancer trial results announced th...
